This company has been marked as potentially delisted and may not be actively trading. NYSE:BIOA (BIOA) (BIOA) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOwnershipTrendsBuy This Stock About (BIOA) Stock (NYSE:BIOA) 30 days 90 days 365 days Advanced Chart Get (BIOA) alerts:Sign Up Key Stats Today's Range$4.40▼$5.0050-Day Range N/A52-Week Range$2.88▼$26.62Volume512,188 shsAverage Volume505,557 shsMarket Capitalization$141.64 millionP/E RatioN/ADividend YieldN/APrice Target$5.67Consensus RatingReduce Company OverviewBioAmber Inc. (BioAmber), formerly DNP Green Technology, Inc., is an industrial biotechnology company, which produces sustainable chemicals. The Company's technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products. Its geographical segments include Europe and North America. Its product pipeline includes the derivatives of bio-succinic acid, such as 1,4 Butanediol (1,4 BDO) and tetrahydrofuran (THF), and succinic acid-based polyesters, and C6 building block chemicals, such as adipic acid, caprolactam and hexamethylenediamine (HMDA). Its products are used in various applications, including polyurethanes, resins and coatings, de-icing and coolant solutions, fine chemicals, lubricants, carpets, engineering plastics and artificial leather products.Read More… Receive BIOA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for (BIOA) and its competitors with MarketBeat's FREE daily newsletter. Email Address BIOA Stock News HeadlinesWith 44% stake, BioAge Labs, Inc. (NASDAQ:BIOA) seems to have captured institutional investors' interestMay 6 at 5:04 PM | finance.yahoo.comBioAge Labs Reports First Quarter 2025 Financial Results and Provides Business UpdatesMay 6 at 4:30 PM | globenewswire.comAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadMay 6, 2025 | American Hartford Gold (Ad)The European Commission refers lecanemab decision to Appeal CommitteeApril 1, 2025 | finance.yahoo.comJefferies Reaffirms Their Hold Rating on BioAge Labs, Inc. (BIOA)March 23, 2025 | markets.businessinsider.comBioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024March 20, 2025 | globenewswire.comFinal Deadline for the BioAge Labs, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - BIOAMarch 10, 2025 | prnewswire.comBIOA Deadline Today: BIOA Investors Have Opportunity to Lead BioAge Labs, Inc. Securities LawsuitMarch 10, 2025 | prnewswire.comSee More Headlines BIOA Stock Analysis - Frequently Asked Questions How were (BIOA)'s earnings last quarter? (BIOA) (NYSE:BIOA) announced its quarterly earnings results on Thursday, November, 7th. The biotechnology company reported ($6.70) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.62) by $6.08. When did (BIOA) IPO? (BIOA) (BIOA) raised $198 million in an initial public offering on Thursday, September 26th 2024. The company issued 11,000,000 shares at a price of $18.00 per share. When did the company's lock-up period expire? (BIOA)'s lock-up period expired on Tuesday, March 25th. (BIOA) had issued 11,000,000 shares in its IPO on September 26th. The total size of the offering was $198,000,000 based on an initial share price of $18.00. Shares of the company owned by company insiders and major shareholders are now eligible to be traded as a result of the expiration of the lock-up period. Who are (BIOA)'s major shareholders? Top institutional investors of (BIOA) include Bailard Inc. (0.07%), Bank of New York Mellon Corp (0.06%), Vontobel Holding Ltd. (0.03%) and Rhumbline Advisers (0.03%). Insiders that own company stock include Vijay Satyanand Pande and Shane Barton. View institutional ownership trends. What other stocks do shareholders of (BIOA) own? Based on aggregate information from My MarketBeat watchlists, some other companies that (BIOA) investors own include ProQR Therapeutics (PRQR), Flexion Therapeutics (FLXN), Rite Aid (RAD), LadRx (CYTR), Intellipharmaceutics International (IPCIF), NVIDIA (NVDA) and AbbVie (ABBV). Company Calendar Last Earnings11/07/2024Today5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:BIOA CIK1534287 Webwww.bio-amber.com Phone+1-612-7474423FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$5.67 High Stock Price Target$7.00 Low Stock Price Target$5.00 Potential Upside/Downside+43.4%Consensus RatingReduce Rating Score (0-4)1.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares35,850,000Free FloatN/AMarket Cap$141.64 million OptionableNot Optionable BetaN/A Free Today: Your Guide to Smarter Options TradesLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NYSE:BIOA) was last updated on 5/6/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredREVEALED: Elon’s Secret Master Plan “AGENDA X”REVEALED: Elon's Secret Master Plan "AGENDA X" For almost 30 years, Elon worked on his master plan in secre...Brownstone Research | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredTrump's $500B plan is fueling these monthly dividendsSomething extraordinary happened just 24 hours after Trump returned to office... He signed a document that ...Investors Alley | SponsoredConfidential Economic AdvisoryI've hesitated for months to record this video. The very act of sharing these details makes me deeply uncom...InvestorPlace | SponsoredThe New ElonThe New Face of DOGE? There is now a new, powerful and controversial figure at the heart of the DOGE agenda...Altimetry | SponsoredOur #1 Defense Stock for MayWe've already lost 18 straight simulated war games against China. The good news is, the U.S. military has a...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding (BIOA) Please log in to your account or sign up in order to add this asset to your watchlist. Share (BIOA) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.